Bayer CropScience (506285) Aktievy
Bayer CropScience Limited är verksamt inom tillverkning, försäljning och distribution av insekticider, fungicider, herbicider och diverse andra agrokemiska produkter samt majsfrön i Indien, Tyskland, Bangladesh och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 1/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 6/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 4/6 |
506285 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bayer CropScience Limited Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | ₹4,326.25 |
| 52 veckors högsta | ₹6,539.95 |
| 52 veckors lägsta | ₹4,276.85 |
| Beta | 0.25 |
| 1 månads förändring | -10.40% |
| 3 månaders förändring | -9.87% |
| 1 års förändring | -14.47% |
| 3 års förändring | 4.76% |
| 5 års förändring | -18.18% |
| Förändring sedan börsintroduktionen | 5,668.34% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • May 01
506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.Uppdatering av berättelse • Apr 17
506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.Uppdatering av berättelse • Apr 02
506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.Uppdatering av berättelse • Mar 19
506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Mar 04
506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).Recent updates
Uppdatering av berättelse • May 01
506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.Uppdatering av berättelse • Apr 17
506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.Uppdatering av berättelse • Apr 02
506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.Uppdatering av berättelse • Mar 19
506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Mar 04
506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).Uppdatering av berättelse • Feb 17
506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook
Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).Uppdatering av berättelse • Feb 03
506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.Uppdatering av berättelse • Jan 20
506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.Uppdatering av berättelse • Jan 05
506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.Uppdatering av berättelse • Dec 21
506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year
Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.Uppdatering av berättelse • Dec 07
506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025
Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.Uppdatering av berättelse • Nov 23
506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025
Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.Ny berättelse • May 18
Seeds, Traits And Biofuels Will Unlock New Value Pools
Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.Aktieägarnas avkastning
| 506285 | IN Chemicals | IN Marknad | |
|---|---|---|---|
| 7D | -0.8% | 0.7% | 0.5% |
| 1Y | -14.5% | -2.6% | -0.7% |
Avkastning vs industri: 506285 presterade sämre än Indian Chemicals branschen som gav -2.6 % under det senaste året.
Avkastning vs Marknaden: 506285 presterade sämre än Indian marknaden som gav -0.7 % under det senaste året.
Prisvolatilitet
| 506285 volatility | |
|---|---|
| 506285 Average Weekly Movement | 3.9% |
| Chemicals Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
Stabil aktiekurs: 506285 har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Indian.
Volatilitet över tid: 506285 s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1896 | 1,169 | Simon-Thorsten Wiebusch | www.bayer.in |
Bayer CropScience Limited är verksamt inom tillverkning, försäljning och distribution av insekticider, fungicider, herbicider och diverse andra agrokemiska produkter samt majsfrön i Indien, Tyskland, Bangladesh och internationellt. Företaget tillhandahåller läkemedel främst inom terapiområdena kardiologi, gynekologi, diabetes, onkologi och oftalmologi samt utrustning för datortomografi, röntgen och magnetisk resonanstomografi. Dessutom erbjuder företaget konsumenthälsoprodukter som används som en daglig hälsolösning för att behandla mindre sjukdomar, samt säljer och distribuerar hybridfrön, såsom majs och paddy.
Bayer CropScience Limited Sammanfattning av grunderna
| 506285 grundläggande statistik | |
|---|---|
| Börsvärde | ₹194.13b |
| Vinst(TTM) | ₹6.70b |
| Intäkter(TTM) | ₹56.21b |
29.0x
P/E-förhållande3.5x
P/S-förhållandeÄr 506285 övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| 506285 resultaträkning (TTM) | |
|---|---|
| Intäkter | ₹56.21b |
| Kostnad för intäkter | ₹34.00b |
| Bruttovinst | ₹22.21b |
| Övriga kostnader | ₹15.50b |
| Intäkter | ₹6.70b |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
May 26, 2026
| Vinst per aktie (EPS) | 149.17 |
| Bruttomarginal | 39.51% |
| Nettovinstmarginal | 11.93% |
| Skuld/egenkapitalförhållande | 3.3% |
Hur har 506285 utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
2.9%
Aktuell utdelningsavkastning84%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 11:47 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Bayer CropScience Limited bevakas av 26 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |